ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported Q2 2026 total revenue of $19.2 million and narrowed its net loss to $16.6 million, or $0.11 per share, helped by a 17% workforce reduction and operational efficiencies that are expected to generate $10 million in annualized savings. However, the company faces a major regulatory hurdle after the FDA noted substantial concerns regarding the benefit-risk profile of the LOTIS-5 confirmatory trial, citing an imbalance in Grade 5 events relative to the marginal treatment benefit, leaving the path to full approval uncertain.
Key figures
- Revenue
- 19248000
- Net loss
- $16.6 million
- Cash balance
- $219.1 million
- Product revenue
- $18.6 million
- Workforce reduction
- 17%
- Restructuring savings
- $10 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.